VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Size is predicted to expand with a 6.8% CAGR during the forecast period for 2025-2034.
Inhibitors of VEGF (Vascular Endothelial Growth Factor) are a standard treatment for diabetic retinopathy, particularly in cases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME). These medications function by targeting VEGF, a protein that promotes the formation of abnormal blood vessels and increases vascular permeability in the retina, two key mechanisms underlying the progression of diabetic retinopathy. Elevated VEGF levels in the diabetic retina led to neovascularization, increased vascular leakage, causing macular edema, and progressive retinal damage, which can result in vision loss. By blocking VEGF activity, these inhibitors prevent the growth of abnormal blood vessels, reduce fluid leakage and retinal swelling, and ultimately help to stabilize or even improve visual acuity in affected patients.
Ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor, is a key treatment for diabetic retinopathy, including diabetic macular edema (DME). It works by inhibiting the formation of abnormal new blood vessels and reducing fluid leakage in the retina, two hallmark features of diabetic retinopathy. Ranibizumab is a recombinant humanized monoclonal antibody fragment that selectively binds to VEGF-A, a protein that promotes angiogenesis, thereby effectively suppressing disease progression. Alongside ranibizumab, other VEGF inhibitors such as aflibercept, bevacizumab, and faricimab have demonstrated strong clinical efficacy in reducing macular edema and improving or stabilizing vision. Growing emphasis on early detection and treatment, supported by advancements in non-invasive imaging and teleophthalmology, further supports the expanding role of anti-VEGF therapies in the management of diabetic retinopathy.
Some of the Major Key Players in the VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market are:
The VEGF inhibitors therapeutic for the diabetic retinopathy market is segmented based on drug type, indication, and delivery method. Based on Drug Type, the market is segmented into aflibercept, ranibizumab, bevacizumab, faricimab, biosimilars, and pipeline drugs. Based on the Indication, the market is divided into diabetic macular edema (DME), proliferative. diabetic retinopathy (PDR), non-proliferative diabetic retinopathy (NPDR). Based on the delivery method, the market is divided into intravitreal injections, sustained-release implants, and emerging technologies.
Based on Drug Type, the market is segmented into aflibercept, ranibizumab, bevacizumab, faricimab, biosimilars, and pipeline drugs. the aflibercept (Eylea) segment is expected to have the highest growth rate during the forecast period. Eylea has demonstrated strong clinical efficacy in stabilizing and improving vision in patients with retinal diseases. It is approved for multiple indications, including wet age-related macular degeneration (AMD), DME, and diabetic retinopathy, making it a versatile treatment option. The introduction of Eylea HD, an 8 mg high-dose formulation, allows for longer intervals between injections (up to 16 weeks), reducing the treatment burden on patients and healthcare providers.
Based on the Indication, the market is divided into diabetic macular edema (DME), proliferative. diabetic retinopathy (PDR), non-proliferative diabetic retinopathy (NPDR). Among these, the non-proliferative diabetic retinopathy (NPDR) segment dominates the market. There's a growing emphasis on early detection and treatment of diabetic retinopathy. Initiating anti-VEGF therapy during the NPDR stage can prevent progression to more severe forms, such as Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME). Studies have demonstrated that early treatment of severe NPDR with anti-VEGF agents leads to a significant reduction in the risk of progression to PDR.
The North America region particularly the United States, holds the largest share of the VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market during the forecast period. North America boasts a well-developed healthcare system with widespread access to eye care specialists and advanced diagnostic technologies, which facilitates the early detection and effective treatment of diabetic retinopathy.
The United States, in particular, has a significant diabetic population, contributing to a higher incidence of diabetic retinopathy and a corresponding increase in demand for targeted therapies. Additionally, the region has demonstrated rapid adoption of innovative treatments, including anti-VEGF agents, driven by robust clinical research infrastructure and timely regulatory approvals. These factors collectively support North America's leading position in the VEGF inhibitors therapeutic market for diabetic retinopathy.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 6.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Type, Indication, Delivery Method |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Regeneron Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Genentech, Inc. (Roche subsidiary), Kodiak Sciences Inc, Innovent Biologics, Inc, Ashvattha Therapeutics, Inc, UNITY Biotechnology, Inc, PanOptica, Inc, Regenxbio Inc. Ocular Therapeutix, Inc, Adverum Biotechnologies, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Snapshot
Chapter 4. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on VEGF Inhibitors Therapeutic for Diabetic Retinopathy Industry Trends
4.10. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 1: By Drug Type, Estimates & Trend Analysis
5.1. Market Share by Drug Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
5.2.1. Aflibercept (Eylea)
5.2.2. Ranibizumab (Lucentis)
5.2.3. Bevacizumab (Avastin, off-label)
5.2.4. Faricimab (Vabysmo, dual VEGF/Ang-2 inhibitor)
5.2.5. Biosimilars
5.2.6. Pipeline drugs
Chapter 6. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Diabetic Macular Edema (DME)
6.2.2. Proliferative Diabetic Retinopathy (PDR)
6.2.3. Non-Proliferative Diabetic Retinopathy (NPDR)
Chapter 7. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 3: By Delivery Method, Estimates & Trend Analysis
7.1. Market Share by Delivery Method, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Method:
7.2.1. Intravitreal Injections
7.2.2. Sustained-Release Implants
7.2.3. Emerging
Chapter 8. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.2.3. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.2.4. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.3. Europe
8.3.1. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.3.3. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.3.4. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.4.3. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.4.4. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.5. Latin America
8.5.1. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.5.3. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.5.4. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.6.3. Middle East & Africa VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.6.4. Middle East & Africa VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Regeneron Pharmaceuticals, Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Drug Type/Service Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Blue Diamond Growers, Inc.
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.4. Novartis AG
9.2.5. Bayer AG
9.2.6. Genentech, Inc. (Roche subsidiary)
9.2.7. Kodiak Sciences Inc.
9.2.8. Innovent Biologics, Inc.
9.2.9. Ashvattha Therapeutics, Inc.
9.2.10. UNITY Biotechnology, Inc.
9.2.11. PanOptica, Inc.
9.2.12. Regenxbio Inc.
9.2.13. Ocular Therapeutix, Inc.
9.2.14. Adverum Biotechnologies, Inc
Segmentation of VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market
Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market - By Drug Type
Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market – By Indication
Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market – By Delivery Method
Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market – By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
